A Phase I Trial of ABT-263 (Navitoclax), a Bcl-2 Inhibitor, and Sorafenib (Nexavar) in Patients With Relapsed or Refractory Solid Organ Tumors
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Sep 2019
Price : $35 *
At a glance
- Drugs Navitoclax (Primary) ; Sorafenib (Primary)
- Indications Liver cancer; Solid tumours
- Focus Adverse reactions
- 01 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 15 May 2019 Planned primary completion date changed from 1 Nov 2018 to 7 May 2020.
- 31 Aug 2018 Biomarkers information updated